Home

breadcrumb-icon

Medicamen Biotech Ltd Screener

₹ 532.61 Cr.

75.11

2.07 %

₹ 395.25

₹ 190.03

3.34 %

₹ 630/375.05

0.24 %

₹ 1

icon

Small Cap

With a marketcap of ₹ 532.61 Cr Stock is ranked 1871

Medicamen Biotec Investment Return

Short Term

-2.96 %

-0.97 %

-14.43 %

-19.98 %


Long Term

-13.61 %

-43.75 %

0.79 %

2092.76 %

Medicamen Biotec Return Calculator


₹ 0

0

₹ 0

Medicamen Biotec Revenue and Profit and Growth

Strength

  • The company's Book Value Per Share (BVPS) is improving consistently for last 2 years

Weakness

  • The Price of Rs. 449.1 of the company is under its 50 Day SMA of Rs 508.15, 100 Day SMA of Rs 472.07, 200 Day SMA of Rs 475.16 and 20 Day EMA of Rs 492.99
  • There is an increase in the provisions made by the company.as per its recent filings.
  • RSI of the company is 40.99
  • Mutual Funds have decreased their shareholding last quarter in the company

Medicamen Biotec Screener FAQs

What types of data can I screen with a Medicamen Biotec screener?

The Medicamen Biotec screener can be used to check different types of data, such as market capitalization, stock P/E, PB ratio, current price, book value, ROE, 52W high/low, dividend yield, and face value. It also shows short-term and long-term data of the Medicamen Biotec.

What is the importance of using a stock screener for analyzing Medicamen Biotec?

You can use the Medicamen Biotec stock screener to analyze stocks based on specific criteria, helping you choose stocks for investments based on real-time data.

Is the Medicamen Biotec Stock Screener suitable for both short-term and long-term investors?

Yes, you can use the Medicamen Biotec Stock Screener for both short-term and long-term. Using the short term, you can check data for periods ranging from 1 week to 6 months. On the other hand, if you are looking to invest long-term, you can check data for periods ranging from 1 year to 10 years.

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions